Prevalence and nature of cardiovascular disease in methamphetamine-related death: A national study

Drug and Alcohol Dependence

Volumn 179, Issue , 2017, Pages 174-179

  Darke, Shane ^a   Duflou, Johan ^a,b   Kaye, Sharlene ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c JUSTICE HEALTH AND FORENSIC MENTAL HEALTH NETWORK   (Australia)

Author keywords

Cardiovascular; Disease; Heart; Methamphetamine; Mortality

Indexed keywords

METHAMPHETAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; TOXICOLOGY; AMPHETAMINE DEPENDENCE; AUSTRALIA; CARDIAC MUSCLE; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; PATHOLOGY; PATHOPHYSIOLOGY;

AMPHETAMINE-RELATED DISORDERS; AUSTRALIA; CORONARY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; HYPERTENSION; MALE; METHAMPHETAMINE; MYOCARDIUM; PREVALENCE;

EID: 85026875723     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.07.001     Document Type: Article

References (30)

1. Callaghan, R.C., Cunningham, J.K., Verdichevski, M., Sykes, J., Jaffer, S.R., Kish, S.J., All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alcohol Depend. 125 (2012), 290–294.
2. Codd, M.B., Sugrue, D.D., Gersh, B.J., Melton, L.J., Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy a population-based study in Olmsted County, Minnesota, 1975–1984. Circulation 80 (1989), 564–572.
3. Darke, S., Farrell, M., Which medications are suitable for agonist drug maintenance?. Addict 111 (2016), 767–774.
4. Darke, S., Kaye, S., McKetin, R., Duflou, J., The major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 27 (2008), 253–262.
5. Darke, S., Torok, M., Kaye, S., Duflou, J., Cardiovascular disease risk factors and symptoms amongst regular psychostimulant users. Drug Alcohol Rev. 29 (2010), 371–377.
6. Darke, S., Kaye, S., McKetin, R., Duflou, J., Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7 year study. Addict, 2017.
7. Degenhardt, L., Hall, W., Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379 (2012), 55–70.
8. Degenhardt, L., Whiteford, H.A., Ferrari, A.J., Baxter, A.J., Charlson, F.J., Hall, W.D., Freedman, G., Burstein, R., Johns, N., Engell, R.E., Flaxman, A., Murray, C., Flaxman, A., Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 382 (2013), 1564–1574.
9. Fairweather, D., Cooper, L.T., Blauwet, L.A., Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr. Probl. Cardiol. 38 (2013), 7–46.
10. Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M., Heit, J.A., Howard, V.J., Huffman, M.D., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Magid, D., Marcus, G.M., Marelli, A., Matchar, D.B., McGuire, D.K., Mohler, E.R., Moy, C.S., Mussolino, M.E., Nichol, G., Paynter, N.P., Schreiner, P.J., Sorlie, P.D., Stein, J., Turan, T.N., Virani, S.S., Wong, N.D., Woo, D., Turner, M.B., American Heart Association Statistics Committee and Stroke Statistics Subcommittee, 2013 heart disease and stroke statistics—2013 update. A report from the American Heart Association. Circulation 127 (2013), e6–e245.
11. Huang, M.C., Yang, S.Y., Lin, S.K., Chen, K.Y., Chen, Y.Y., Kuo, C.J., Hung, Y.N., Risk of in methamphetamine cardiovascular diseases and stroke events users: a 10-year follow-up study. J. Clin. Psychiatry, 77, 2016, 1396.
12. IBM, SPSS Statistics, 23.0. 2015, IBM, Chicago.
13. Karch, S.B., Stephens, B.G., Ho, C.H., Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicological profiles. J. Forens. Sci. 44 (1999), 359–368.
14. Karch, S.B., Karch's Pathology of Drug Abuse. 4th edition, 2009, CRC Press, Boca Raton.
15. Kaye, S., McKetin, R., Duflou, J., Darke, S., Methamphetamine and cardiovascular pathology: a review of the evidence. Addict 102 (2007), 1204–1211.
16. Kaye, S., Darke, S., McKetin, R., Duflou, J., Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addict 103 (2008), 1353–1360.
17. Kitzman, D.W., Scholz, D.G., Hagen, P.T., Ilstrup, D.M., Edwards, W.D., Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity): A quantitative anatomic study of 765 specimens from subjects 20–99 years old. Mayo Clin. Proc. 63 (1988), 137–146.
18. Logan, B., Fligner, C.L., Haddix, T., Cause and manner of death in fatalities involving methamphetamine. J. Forens. Sci. 43 (1998), 28–34.
19. Mahmood, S.S., Levy, D., Vasan, R.S., Wang, T.J., The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 383 (2014), 999–1008.
20. Marshall, B.D., Werb, D., Health outcomes associated with methamphetamine use among young people: a systematic review. Addict 105 (2010), 991–1002.
21. McKetin, R., Najman, J.M., Baker, A.L., Lubman, D.I., Dawe, S., Ali, R., Lee, N.K., Mattick, R.P., Mamun, A., Evaluating the impact of community-based treatment options on methamphetamine use: findings from the methamphetamine treatment evaluation study (MATES). Addict 107 (2012), 1998–2008.
22. Meyer, S., van der Meer, P., van Tintelen, J.P., van den Berg, M.P., Sex differences in cardiomyopathies. Euro. J. Heart Failure 16 (2014), 238–247.
23. Moon, K., Albuquerque, F.C., Mitkov, M., Ducruet, A.F., Wilson, D.A., Crowley, R.W., Nakaji, P., McDougall, C.G., Methamphetamine use is an independent predictor of poor outcome after aneurysmal subarachnoid haemorrhage. J. Neurointerv. Surg. 7 (2015), 346–350.
24. Neeki, M.M., Kulczycki, M., Toy, J., Dong, F., Lee, C., Borger, R., Adigopula, S., Frequency of methamphetamine use as a major contributor toward the severity of cardiomyopathy in adults≤ 50 years. Am. J. Cardiol. 118 (2016), 585–589.
25. Singleton, J., Degenhardt, L., Hall, W., Zabransky, T., Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 105 (2009), 1–8.
26. Stock, E.O., Redberg, R., Cardiovascular disease in women. Curr. Probl. Cardiol. 37 (2012), 450–526.
27. United Nations Office on Drugs and Crime, World Drug Report 2016. United Nations New York., 2016.
28. Voskoboinik, A., Ihl, J.F., Bloom, J.E., Kaye, D.M., Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Int. Med. J. 46 (2016), 723–727.
29. Yeo, K.K., Wijetunga, M., Ito, H., Efird, J.T., Tay, K., Alimineti, Seto, Kimata, K., Schatz, C.T.B., The association of methamphetamine use and cardiomyopathy in young patients. Am. J. Med. 120 (2007), 165–171.
30. Zhu, B.L., Oritani, S., Shimotouge, K., Ishida, K., Quan, L., Fujita, M.Q., Ogawa, M., Maeda, H., Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas. Forens. Sci. Int. 113 (2000), 443–447.